Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Glucose-dependent insulinotropic peptide (GIP) is known to be degraded by dipeptidyl peptidase IV (DPP IV), forming an inactive metabolite, but the extent of the enzyme’s role in regulating the biological activity of GIP in vivo is still largely unknown. In nonfasted anesthetized pigs given an intravenous infusion of GIP, the intact peptide (determined by a novel NH2-terminally directed radioimmunoassay) accounts for only 14.5 ± 2.5% of total immunoreactivity. This is increased (to 40.9 ± 0.9%, P < 0.0001) by coadministration of valine-pyrrolidide (a specific DPP IV inhibitor) at a dose that completely inhibits plasma DPP IV activity. The plasma t1/2 of intact GIP is prolonged by the inhibitor (from 3.3 ± 0.3 to 8.1 ± 0.6 min; P < 0.001), whereas the t1/2 for COOH-terminal immunoreactivity is unaffected (13.2 ± 0.5 and 11.5 ± 0.8 min, pre- and postinhibitor). Measurement of arteriovenous concentration differences revealed that the liver, kidney, and extremities are the main sites of removal of exogenous intact GIP (organ extractions, 28.0 ± 2.2, 26.3 ± 5.7, and 21.8 ± 3.0%, respectively). These organ extractions are reduced (P < 0.02) but not eliminated (kidney and extremities) by valine-pyrrolidide (to 6.5 ± 4.6, 14.1 ± 3.1, and 13.9 ± 2.4%, respectively). Valine-pyrrolidide potentiates the insulinotropic effect of GIP (P < 0.02), resulting in an enhanced glucose disappearance rate (k, from 8.0 ± 0.5 to 15.5 ± 2.2%/min; P < 0.01) and a reduction in the glucose excursion after an intravenous glucose load (area under the curve, from 133 ± 23 to 75 ± 9 min · mmol/l; P < 0.05). These results suggest that DPP IV plays an important role in GIP metabolism but is not the sole enzyme responsible for its NH2-terminal degradation. Nevertheless, DPP IV inhibition increases the proportion of intact peptide sufficiently to enhance its insulinotropic and antihyperglycemic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 1×
“(24), using HPLC to follow degradation of radiolabeled GIP in rats, showed that the peptide was rapidly cleaved at the NH2-terminus in normal animals but not in a DPP IV– deficient strain, suggesting a role for the enzyme in vivo.”
MethodSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“for NH2-terminal degradation of GLP-1 in plasma (4,18).”
BackgroundSelf-citationGIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266 · cited 1×
“GIP has also been indicated to increase the affinity of the insulin receptor (40), giving rise to the suggestion that GIP can modulate the effects of insulin by directly altering target tissue sensitivity to insulin (38), thereby contributing to the effective uptake of glucose postprandially (39,41).”
BackgroundExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Functional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
PEDERSON, R. A., & BROWN, J. C. (1978) · Endocrinology · doi:10.1210/endo-103-2-610 · Cited by 156 · cited 1×
“In contrast, GIP has a glucagonotropic effect in isolated a-cells (46), isolated pancreatic islets (47,48), perfused rat pancreata (49), and porcine pancreata (J.”
BackgroundEffects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes
Hauner, H., Glatting, G., Kaminska, D., & Pfeiffer, E. F. (1988) · Annals of Nutrition and Metabolism · doi:10.1159/000177467 · Cited by 98
O'Harte, F., Gray, A., & Flatt, P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1560237 · Cited by 60 · cited 1×
“GIP receptors have been identified in several tissues (34,35), and there are reports that GIP promotes glucose uptake in muscle (36) and fat (37–39).”
Background
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
The incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
Self-citationIncretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
Self-citationPhysiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
Self-citation
Metadata
- Authors
- Deacon, C. F., Danielsen, P., Klarskov, L., Olesen, M., & Holst, J. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2001-07-01
- Volume
- 50
- Issue
- 7
- Pages
- 1588-1597
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2104239190
- Cited by
- 145
- References
- 11
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs. https://app.cochat.ai/papers/10.2337/diabetes.50.7.1588
- The paper
- Deacon, C. F., Danielsen, P., Klarskov, L., Olesen, M., & Holst, J. J. (2001). Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs. Diabetes. https://doi.org/10.2337/diabetes.50.7.1588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.